Vivos Therapeutics (VVOS) Expected to Post Earnings on Wednesday

Vivos Therapeutics (NASDAQ:VVOS) is expected to announce its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $5.47 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 5:00 PM ET.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.10. The company had revenue of $5.15 million for the quarter, compared to analyst estimates of $5.63 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%. On average, analysts expect Vivos Therapeutics to post ($1.30) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Vivos Therapeutics Stock Performance

Shares of VVOS stock opened at $0.09 on Wednesday. The stock’s 50-day moving average is $0.14 and its two-hundred day moving average is $0.69. Vivos Therapeutics has a 1 year low of $0.09 and a 1 year high of $2.72. The firm has a market cap of $1.74 million, a price-to-earnings ratio of -0.05 and a beta of 6.37.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $2.80.

About Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.